Loading clinical trials...
Loading clinical trials...
Conditions
Interventions
High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)
High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)
+3 more
Locations
16
United States
Investigational Site Number 8400004
San Diego, California, United States
Investigational Site Number 8400001
Miami, Florida, United States
Investigational Site Number 8400002
Atlanta, Georgia, United States
Investigational Site Number 8400013
El Dorado, Kansas, United States
Investigational Site Number 8400015
Newton, Kansas, United States
Investigational Site Number 8400009
Wichita, Kansas, United States
Start Date
October 9, 2018
Primary Completion Date
October 16, 2019
Completion Date
October 16, 2019
Last Updated
April 4, 2022
NCT07291635
NCT06094010
NCT06417762
NCT06160128
NCT07396428
NCT07310472
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions